Navigation Links
New oncogene identified for breast cancer
Date:8/13/2012

A team of researchers at Case Western Reserve University School of Medicine, led by Dr. Mark W. Jackson, have developed a novel method to identify genes that, when overexpressed, make normal cells behave like cancer cells. Using this method, the Jackson laboratory has identified a new oncogene, which is a gene that contributes to the development of cancer, named FAM83B.

"We made our discovery in a model of breast cancer," said Mark W. Jackson, Ph.D., Assistant Professor, Department of Pathology, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center. "Using an unbiased screening approach, we let the biology of cancer formation tell us what genes are important and FAM83B was one of the genes that came out of our screen. When FAM83B was overproduced in normal breast cells, it transformed the normal cells, causing them to behave like breast cancer," stated Jackson.

There are relatively few oncogenes that are critical to breast cancer growth, and only one other breast cancer oncogene has been identified in the last 6 years. Breast cancers are classified clinically into subgroups based on the presence of specific proteins, including estrogen receptor (ER), progesterone receptor (PR), and HER2.

"Analysis of breast cancer revealed that elevated FAM83B expression is associated with the more aggressive, triple negative subgroup which lacks ER, PR and HER2," said Jackson. "In short, patients with triple-negative breast cancer would benefit most from the development of new therapeutics."

Novel oncogenes provide opportunities for drug development that may expand the number of therapies available for eradicating cancer and extending the life of patients. "Our discovery provides the foundation for developing new therapies that can inhibit FAM83B in these aggressive cancers, which have traditionally been difficult to treat." We are currently trying to identify drugs that that can inhibit the function of FAM83B." stated Jackson.

This study will appear in The Journal of Clinical Investigation and will be co-published with a discovery from the laboratory of Dr. Mina Bissell at Lawrence Berkley National Laboratories. Dr. Bissell's laboratory discovered an oncogene called FAM83A. Both FAM83A and FAM83B belong to an eight member family of genes that both laboratories propose may drive tumor formation and therapeutic resistance.


'/>"/>

Contact: Christine Somosi
christine.somosi@case.edu
216-368-6287
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Predictors identified for rehospitalization among post-acute stroke patients
2. 2 repressor genes identified as essential for placental development
3. Possible new cancer treatment identified
4. Gene Behind Psoriasis Identified, Researchers Say
5. A microRNA prognostic marker identified in acute leukemia
6. Early biomarker for pancreatic cancer identified
7. The cells petrol pump is finally identified
8. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
9. New cerebellar ataxia gene identified in dogs
10. Misidentified and contaminated cell lines lead to faulty cancer science
11. Germ Culprits in Moldy, Water-Damaged Buildings Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ... July 22, 2017 , ... The ... cuff repairs the opportunity to return to sports and jobs that require heavy ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. , “We ...
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick ... planning services to families and business owners in northern Florida, is joining the ... provide support to area adults with developmental challenges. , The First Coast YMCA ...
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the second ... of hospital acquisitions rose to 23 in the second quarter, up 15% from the ... the 20 announced deals in the year-ago second quarter. Only four of the transactions ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched ... of acceptance to a residency in a United States hospital. Being accepted into ... U.S. , According to data released by the ECFMG®, every year, 50 percent ...
(Date:7/21/2017)... ... July 21, 2017 , ... The most common ... improved quality of life five years after injury, according to research presented today ... Toronto, Ontario, Canada. The study followed patients for five years following surgery. , ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... RK Logistics Group, Inc. was awarded ... Fremont, CA headquarters facility where it ... San Jose for hi-tech, pharmaceutical and ... , with its Fremont Innovation District, is excited to strategically ... resource to the hundreds of biotech, pharma and biomed companies ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is ... to patients who suffer from painful intercourse and other painful pelvic pain ... atrophy due to menopause. ... VuVatech LLC ... by Sarasota, Florida -based start-up company, VuVatech LLC, fills ...
Breaking Medicine Technology: